Targeting the chemokine receptor CXCR4 with histamine analogue to reduce inflammation in juvenile arthritis: a proof of concept for COVID-19 therapeutic approach
N. Bekaddour, N. Smith, B. Beitz, A. Llibre, T. Dott, A. Baudry, A.-S. Korganow, S. Nisole, R. Mouy, S. Breton, B. Bader-Meunier, D. Duffy, B. Terrier, B. Schneider, P. Quartier, , J.-P. Herbeuval
This study shows that targeting CXCR4 with clobenpropit reduces inflammation in juvenile arthritis and COVID-19 by lowering cytokine levels and immune cell activity.
bioRxiv · Oct 24, 2021 · PreprintImmunology